InvestSMART

Mesoblast Limited (ASX: MSB) - Announcements

- Current share price for MSB : $2.230

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mesoblast Limited (MSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mesoblast Limited (MSB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,896 Quarterly Activities/Appendix 4C Cash Flow Report 30 Apr 2026 9:56AM $2.220 $2.230 risen by 0.45%
$2,896 Patient Recruitment Target Achieved in CLBP Pivotal Trial 29 Apr 2026 9:50AM $2.150 $2.230 risen by 3.72%
$2,896 Appendix 3Y for Gregory George 16 Apr 2026 5:22PM $2.240 $2.230 fallen by 0.45%
$2,896 Notification of cessation of securities - MSB 16 Apr 2026 5:13PM $2.240 $2.230 fallen by 0.45%
$2,896 Notification regarding unquoted securities - MSB 16 Apr 2026 5:09PM $2.240 $2.230 fallen by 0.45%
$2,896 Application for quotation of securities - MSB 16 Apr 2026 5:05PM $2.240 $2.230 fallen by 0.45%
$2,896 Notification regarding unquoted securities - MSB 16 Apr 2026 5:03PM $2.240 $2.230 fallen by 0.45%
$2,896 Acquires CAR Platform for Precision-Enhanced Cell Products 15 Apr 2026 9:25AM $2.010 $2.230 risen by 10.95%
$2,896 Mesoblast R&D Day Presentation 8 Apr 2026 7:16PM $2.020 $2.230 risen by 10.40%
$2,896 Mesoblast R&D Day Features Commercial & Blockbuster Programs 8 Apr 2026 7:08PM $2.020 $2.230 risen by 10.40%
$2,896 FDA Clears Ryoncil IND for Registration Trial in DMD 8 Apr 2026 12:31PM $1.978 $2.230 risen by 12.77%
$2,896 Application for quotation of securities - MSB 8 Apr 2026 10:00AM $2.070 $2.230 risen by 7.73%
$2,896 Cleansing Notice 8 Apr 2026 9:54AM $1.985 $2.230 risen by 12.34%
$2,896 Proposed issue of securities - MSB 7 Apr 2026 5:19PM $1.985 $2.230 risen by 12.34%
$2,896 Ryoncil Net Revenue for the Quarter Increases to US$30.3M 7 Apr 2026 10:12AM $2.135 $2.230 risen by 4.45%
$2,896 Appendix 3Ys - S Itescu, E Rose, G George and L Cobley 20 Mar 2026 5:23PM $2.060 $2.230 risen by 8.25%
$2,896 Notification regarding unquoted securities - MSB 20 Mar 2026 4:51PM $2.060 $2.230 risen by 8.25%
$2,896 Mesoblast to Host R&D Day on April 8, 2026 18 Mar 2026 9:54AM $2.020 $2.230 risen by 10.40%
$2,896 Replacement Appendix 3Y for Gregory George 12 Mar 2026 5:05PM $2.140 $2.230 risen by 4.21%
$2,896 Appointment of Clinical Development and Medical Affairs Head 12 Mar 2026 9:58AM $2.190 $2.230 risen by 1.83%
$2,896 Becoming a substantial holder 10 Mar 2026 3:28PM $2.170 $2.230 risen by 2.76%
$2,896 Appendix 3Y for Gregory George 10 Mar 2026 9:39AM $2.110 $2.230 risen by 5.69%
$2,896 Change in substantial holding 9 Mar 2026 11:33AM $2.120 $2.230 risen by 5.19%
$2,896 Ryoncil Profits Underpinning Substantial Growth Pipeline 27 Feb 2026 9:02AM $2.420 $2.230 fallen by 7.85%
$2,896 Corporate Presentation and Half Year Financial Results 27 Feb 2026 8:49AM $2.420 $2.230 fallen by 7.85%

26 - 50 of 1178 results

Page 2 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.